<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>Intellia Therapeutics ( (NTLA) ) has provided an update. On April 27, 2026, Intellia Therapeutics reported positive topline Phase 3 results from its global HAELO trial of lonvoguran ziclumeran, an in vivo CRISPR-based, one-time gene-editing therapy for hereditary angioedema. The randomized, double-blind, placebo-controlled study enrolled 80 patients and showed that a single 50 mg infusion cut monthly attack rates by 87% versus placebo over weeks 5 to 28. The trial also met all key secondary endpoints, with 62% of lonvo-z patients remaining both attack-free and therapy-free over six months, and all treated patients seeing reduced attack rates from baseline. Safety data were favorable, with only mild to moderate adverse events and no serious events in the lonvo-z arm, and all treated patients remaining off long-term prophylaxis as of the February 10, 2026 data cutoff. Intellia simultaneously began a rolling biologics license application with the U.S. Food and Drug Administration for lonvo-z in hereditary angioedema, positioning the therapy as a potential first one-time treatment in this market. If approved, a planned U.S. launch in 2027 could mark a watershed moment for in vivo gene editing and significantly strengthen Intellia’s competitive standing in both the rare-disease and broader precision-medicine arenas. The most recent analyst rating on (NTLA) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page. Spark’s Take on NTLA Stock According to Spark, TipRanks’ AI Analyst, NTLA is a Neutral. The score is held back primarily by weak financial performance—persistent losses, volatile revenue, and ongoing cash burn—despite a comparatively solid solvency profile. Technicals are moderately supportive with price above key moving averages and positive MACD. Clinical/program progress and reiterated timelines from the earnings call help, but safety/regulatory uncertainty and funding/dilution considerations temper the outlook. To see Spark’s full report on NTLA stock, click here. More about Intellia Therapeutics Intellia Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on using CRISPR gene editing and related technologies to develop potentially curative treatments for severe diseases. Based in Cambridge, Mass., the Nasdaq-listed firm aims to reset standards of care by durably treating underlying genetic drivers rather than managing symptoms over a patient’s lifetime. The company’s pipeline includes in vivo gene-editing candidates such as lonvoguran ziclumeran (lonvo-z), which targets the kallikrein B1 gene to lower kallikrein and bradykinin levels. Intellia’s programs concentrate on conditions with significant unmet need, including rare genetic disorders like hereditary angioedema, where existing therapies often require lifelong, frequent dosing and still leave patients at risk of breakthrough attacks. Average Trading Volume: 3,817,885 Technical Sentiment Signal: Buy Current Market Cap: $1.61B For a thorough assessment of NTLA stock, go to TipRanks’ Stock Analysis page.</div>

NTLA

CRSP

WDNA

Intellia Therapeutics reported positive Phase 3 results for its gene therapy, lonvoguran ziclumeran, in treating hereditary angioedema. The trial showed an 87% reduction in monthly attack rates and favorable safety data. Intellia has begun a rolling biologics license application with the FDA, aiming for a 2027 U.S. launch. Analysts rate NTLA stock as a Buy with a $29 price target, though concerns about financial performance and regulatory uncertainties persist. Intellia focuses on CRISPR gene editing to develop treatments for severe diseases, with a market cap of $1.61B.

Intellia Reports Positive Phase 3 Results for HAE Gene Therapy